Molecular pathogenesis of pulmonary arterial hypertension
Marlene Rabinovitch
Marlene Rabinovitch
Published July 1, 2008
Citation Information: J Clin Invest. 2008;118(7):2372-2379. https://doi.org/10.1172/JCI33452.
View: Text | PDF
Science in Medicine

Molecular pathogenesis of pulmonary arterial hypertension

Abstract

Recent investigations have suggested that it might be possible to reverse the pathology of pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal despite current treatments including i.v. prostacyclin. This review will address the cellular and molecular processes implicated in clinical, genetic, and experimental studies as underlying the pulmonary vascular abnormalities associated with PAH. Emerging treatments are aimed at inducing apoptosis of abnormal vascular cells that obstruct blood flow and at promoting regeneration of “lost” distal vasculature.

Authors

Marlene Rabinovitch

×

Figure 2

Schema outlining factors that converge in the molecular pathogenesis of PAH and how these may interact with BMPRII dysfunction, a known genetic defect associated with PAH.

Options: View larger image (or click on image) Download as PowerPoint
Schema outlining factors that converge in the molecular pathogenesis of ...
This schema focuses on factors causing increased SMC and fibroblast proliferation as well as apoptosis of ECs, causing an initial reduction in vessel number, followed by proliferation of apoptosis-resistant ECs in plexiform lesions. It shows multiple levels of interaction, with numerous factors related as described in the text. For example, serotonin stimulates both PDGF-mediated and S100A4/Mts1-mediated SMC and fibroblast proliferation and it also reduces Kv channel function, as does hyperpolarized mitochondria. BMPRII dysfunction causes Kv channel dysfunction and enhances TRP channel activity, which increases intracellular calcium levels, and may (as reflected by question mark) induce elastase activity. Viruses of the herpes family can induce elastase activity. Elastase, via activation of MMPs and tenascin C (TN-C), upregulates growth factor (GF) receptors such as EGF receptors (EGFRs) and also triggers release of growth factors such as EGF from the extracellular matrix, all of which leads to SMC proliferation. BMPRII dysfunction can also increase PDGF activity, increase SMC proliferation by suppressing PPARγ, and increase TGF-β activity. BMPRII dysfunction can enhance inflammation via osteoprotegrin and IL-6. NFATc2 can suppress Kv channel function. Other inflammatory mediators such as fractalkine and MCP-1 can, in addition to osteoprotegrin and IL-6, increase SMC proliferation. BMPRII dysfunction can lead to EC apoptosis, as can elastase activity. EC apoptosis may predispose to the development of apoptosis-resistant ECs in plexiform lesions. MCP-1, mast cell proteinase 1; TRP, transient receptor potential Ca2+ channels.